

Jeffrey A Meyerhardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2931400/publications.pdf>

Version: 2024-02-01

147
papers

15,246
citations

30070

54
h-index

18130

120
g-index

147
all docs

147
docs citations

147
times ranked

17962
citing authors

#	ARTICLE	IF	CITATIONS
1	Smoking and Incidence of Colorectal Cancer Subclassified by Tumor-Associated Macrophage Infiltrates. <i>Journal of the National Cancer Institute</i> , 2022, 114, 68-77.	6.3	17
2	Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial. <i>Journal of Cancer Survivorship</i> , 2022, 16, 882-891.	2.9	14
3	Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2022, 114, 427-435.	6.3	24
4	Long-Term Statin Use, Total Cholesterol Level, and Risk of Colorectal Cancer: A Prospective Cohort Study. <i>American Journal of Gastroenterology</i> , 2022, 117, 158-166.	0.4	13
5	A comprehensive overview of tumour deposits in colorectal cancer: Towards a next TNM classification. <i>Cancer Treatment Reviews</i> , 2022, 103, 102325.	7.7	26
6	Diet- and Lifestyle-Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance). <i>Journal of Clinical Oncology</i> , 2022, 40, 740-751.	1.6	20
7	Coffee Intake of Colorectal Cancer Patients and Prognosis According to Histopathologic Lymphocytic Reaction and T-Cell Infiltrates. <i>Mayo Clinic Proceedings</i> , 2022, 97, 124-133.	3.0	3
8	Plasma metabolomic profiles for colorectal cancer precursors in women. <i>European Journal of Epidemiology</i> , 2022, 37, 413-422.	5.7	11
9	Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. <i>Oncologist</i> , 2022, 27, 292-298.	3.7	2
10	Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. <i>Journal of Geriatric Oncology</i> , 2022, 13, 469-479.	1.0	3
11	Sugar-sweetened beverage and sugar consumption and colorectal cancer incidence and mortality according to anatomic subsite. <i>American Journal of Clinical Nutrition</i> , 2022, 115, 1481-1489.	4.7	16
12	American Cancer Society nutrition and physical activity guideline for cancer survivors. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 230-262.	329.8	228
13	Desmoplastic Reaction, Immune Cell Response, and Prognosis in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 840198.	4.8	9
14	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). <i>Endocrine-Related Cancer</i> , 2022, 29, 335-344.	3.1	8
15	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	7.0	11
16	Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 215-227.	3.4	23
17	Serological testing for SARS-CoV-2 antibodies of employees shows low transmission working in a cancer center. <i>PLoS ONE</i> , 2022, 17, e0266791.	2.5	1
18	Impact of Diet and Exercise on Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 471-489.	2.2	10

#	ARTICLE	IF	CITATIONS
19	Smoking and colorectal cancer survival in relation to tumor LINE-1 methylation levels: a prospective cohort study. , 2022, 2, .		0
20	The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. Journal of the National Cancer Institute, 2021, 113, 1453-1459.	6.3	39
21	The Prognostic Role of Macrophage Polarization in the Colorectal Cancer Microenvironment. Cancer Immunology Research, 2021, 9, 8-19.	3.4	95
22	Risk Factors and Incidence of Colorectal Cancer According to Major Molecular Subtypes. JNCI Cancer Spectrum, 2021, 5, pkaa089.	2.9	11
23	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2021, 5, pkaa074.	2.9	6
24	Moving through cancer: Setting the agenda to make exercise standard in oncology practice. Cancer, 2021, 127, 476-484.	4.1	38
25	Recruitment strategies and design considerations in a trial of resistance training to prevent dose-limiting toxicities in colon cancer patients undergoing chemotherapy. Contemporary Clinical Trials, 2021, 101, 106242.	1.8	13
26	A Modified Tumor-Node-Metastasis Classification for Primary Operable Colorectal Cancer. JNCI Cancer Spectrum, 2021, 5, pkaa093.	2.9	8
27	Unrestrained eating behavior and risk of digestive system cancers: a prospective cohort study. American Journal of Clinical Nutrition, 2021, 114, 1612-1624.	4.7	9
28	Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology, 2021, 39, 325-325.	1.6	2
29	Timing of Aspirin Use in Colorectal Cancer Chemoprevention: A Prospective Cohort Study. Journal of the National Cancer Institute, 2021, 113, 841-851.	6.3	24
30	Tumor Long Interspersed Nucleotide Element-1 (LINE-1) Hypomethylation in Relation to Age of Colorectal Cancer Diagnosis and Prognosis. Cancers, 2021, 13, 2016.	3.7	21
31	Postdiagnostic dairy products intake and colorectal cancer survival in US males and females. American Journal of Clinical Nutrition, 2021, 113, 1636-1646.	4.7	7
32	Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.. Journal of Clinical Oncology, 2021, 39, 3517-3517.	1.6	0
33	Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.. Journal of Clinical Oncology, 2021, 39, 3568-3568.	1.6	0
34	Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).. Journal of Clinical Oncology, 2021, 39, 3588-3588.	1.6	0
35	Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open, 2021, 4, e2112539.	5.9	48
36	Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival. British Journal of Cancer, 2021, 125, 1016-1024.	6.4	9

#	ARTICLE	IF	CITATIONS
37	Abdominal adipose tissue radiodensity is associated with survival after colorectal cancer. American Journal of Clinical Nutrition, 2021, 114, 1917-1924.	4.7	9
38	Unrestrained eating behavior and risk of mortality: A prospective cohort study. Clinical Nutrition, 2021, 40, 5419-5429.	5.0	5
39	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. Journal of Clinical Oncology, 2021, 39, 10-10.	1.6	0
40	Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).. Journal of Clinical Oncology, 2021, 39, 343-343.	1.6	0
41	Dairy intake during adolescence and risk of colorectal adenoma later in life. British Journal of Cancer, 2021, 124, 1160-1168.	6.4	11
42	Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.. Journal of Clinical Oncology, 2021, 39, 361-361.	1.6	1
43	Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers. JAMA Network Open, 2021, 4, e2139593.	5.9	55
44	Determining the optimal duration of adjuvant therapy in colon cancer. Clinical Advances in Hematology and Oncology, 2021, 19, 220-222.	0.3	0
45	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	2.9	22
46	The Association of Abdominal Adiposity With Mortality in Patients With Stage Iâ€”III Colorectal Cancer. Journal of the National Cancer Institute, 2020, 112, 377-383.	6.3	33
47	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectrum, 2020, 4, pkaa024.	2.9	8
48	Association of Low Muscle Mass and Low Muscle Radiodensity With Morbidity and Mortality for Colon Cancer Surgery. JAMA Surgery, 2020, 155, 942.	4.3	91
49	Coffee Intake and Colorectal Cancer Incidence According to T-Cell Response. JNCI Cancer Spectrum, 2020, 4, pkaa068.	2.9	3
50	Smoking Status at Diagnosis and Colorectal Cancer Prognosis According to Tumor Lymphocytic Reaction. JNCI Cancer Spectrum, 2020, 4, pkaa040.	2.9	8
51	Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research, 2020, 13, 1055-1062.	1.5	17
52	Post-diagnosis dietary insulinemic potential and survival outcomes among colorectal cancer patients. BMC Cancer, 2020, 20, 817.	2.6	16
53	An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer. British Journal of Cancer, 2020, 122, 1367-1377.	6.4	21
54	An exercise oncology clinical pathway: Screening and referral for personalized interventions. Cancer, 2020, 126, 2750-2758.	4.1	43

#	ARTICLE	IF	CITATIONS
55	Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors. JNCI Cancer Spectrum, 2020, 4, pkz096.	2.9	14
56	Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts. Journal of Hepatology, 2020, 72, 1062-1069.	3.7	32
57	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. European Journal of Cancer, 2020, 130, 63-71.	2.8	15
58	Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1258-1269.	7.3	79
59	Irinotecan, cetuximab, and bevacizumab (CBI) versus irinotecan, cetuximab, and placebo (CI) in irinotecan-refractory metastatic colorectal cancer (mCRC): Results from an ACCRU network randomized phase II trial.. Journal of Clinical Oncology, 2020, 38, 102-102.	1.6	1
60	Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). Journal of the National Cancer Institute, 2019, 111, 170-179.	6.3	19
61	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. Journal of Clinical Oncology, 2019, 37, 2620-2631.	1.6	51
62	5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. Abdominal Radiology, 2019, 44, 3099-3106.	2.1	14
63	Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma. Journal of Surgical Oncology, 2019, 120, 446-451.	1.7	28
64	The association of medical and demographic characteristics with sarcopenia and low muscle radiodensity in patients with nonmetastatic colorectal cancer. American Journal of Clinical Nutrition, 2019, 109, 615-625.	4.7	45
65	Non-alcoholic fatty liver disease and colorectal cancer survival. Cancer Causes and Control, 2019, 30, 165-168.	1.8	22
66	Smoking and Risk of Colorectal Cancer Sub-Classified by Tumor-Infiltrating T Cells. Journal of the National Cancer Institute, 2019, 111, 42-51.	6.3	30
67	Associations of pre-existing comorbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 654-663.	7.3	55
68	Association of Survival With Adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for Cancer Survivors After Colon Cancer Diagnosis. JAMA Oncology, 2018, 4, 783.	7.1	147
69	Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology, 2018, 67, 1797-1806.	7.3	100
70	Physical Activity and Colorectal Cancer Prognosis According to Tumor-Infiltrating T Cells. JNCI Cancer Spectrum, 2018, 2, pky058.	2.9	10
71	Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2018, 36, 1112-1120.	1.6	50
72	Muscle radiodensity and mortality in patients with colorectal cancer. Cancer, 2018, 124, 3008-3015.	4.1	92

#	ARTICLE	IF	CITATIONS
73	The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage III colorectal cancer: a population-based cohort study (<scp>Câ€SCANS</scp>). Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 664-672.	7.3	80
74	Psychological symptoms and subsequent healthy lifestyle after a colorectal cancer diagnosis.. Health Psychology, 2018, 37, 207-217.	1.6	22
75	Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 1086-1095.	1.6	383
76	Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study). Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1008-1015.	2.5	251
77	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	7.4	670
78	Association of Weight Change after Colorectal Cancer Diagnosis and Outcomes in the Kaiser Permanente Northern California Population. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 30-37.	2.5	53
79	Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The Câ€SCANS study. Cancer, 2017, 123, 4868-4877.	4.1	76
80	Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer. JAMA Oncology, 2017, 3, e172319.	7.1	294
81	Association of Dietary Patterns With Risk of Colorectal Cancer Subtypes Classified by <i>Fusobacterium nucleatum</i> in Tumor Tissue. JAMA Oncology, 2017, 3, 921.	7.1	243
82	Development and Validation of the PREMM₅ Model for Comprehensive Risk Assessment of Lynch Syndrome. Journal of Clinical Oncology, 2017, 35, 2165-2172.	1.6	126
83	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). Journal of Clinical Oncology, 2017, 35, 3671-3677.	1.6	112
84	Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	1.6	110
85	Effect of home-based exercise intervention on fasting insulin and Adipocytokines in colorectal cancer survivors: a randomized controlled trial. Metabolism: Clinical and Experimental, 2017, 76, 23-31.	3.4	43
86	Obesity and Energy Balance in GI Cancer. Journal of Clinical Oncology, 2016, 34, 4217-4224.	1.6	47
87	Analysis of Body Mass Index and Mortality in Patients With Colorectal Cancer Using Causal Diagrams. JAMA Oncology, 2016, 2, 1137.	7.1	126
88	Soluble tumour necrosis factor receptor type II and survival in colorectal cancer. British Journal of Cancer, 2016, 114, 995-1002.	6.4	31
89	Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports, 2016, 15, 857-865.	6.4	671
90	Metabolic Dysfunction, Obesity, and Survival Among Patients With Early-Stage Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 3664-3671.	1.6	69

#	ARTICLE	IF	CITATIONS
91	Cardiopulmonary fitness, adiponectin, chemerin associated fasting insulin level in colorectal cancer patients. Supportive Care in Cancer, 2016, 24, 2927-35.	2.2	3
92	Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. Clinical Cancer Research, 2016, 22, 1489-1498.	7.0	9
93	Association between Body Mass Index and Prognosis of Colorectal Cancer: A Meta-Analysis of Prospective Cohort Studies. PLoS ONE, 2015, 10, e0120706.	2.5	85
94	Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality. Gastroenterology, 2015, 149, 614-622.	1.3	44
95	Role of Physical Activity and Diet After Colorectal Cancer Diagnosis. Journal of Clinical Oncology, 2015, 33, 1825-1834.	1.6	170
96	Prediagnostic Plasma Adiponectin and Survival among Patients with Colorectal Cancer. Cancer Prevention Research, 2015, 8, 1138-1145.	1.5	23
97	Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). Journal of Clinical Oncology, 2015, 33, 3598-3607.	1.6	60
98	Diet and Lifestyle in Survivors of Colorectal Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 1-27.	2.2	43
99	Aspirin and COX-2 Inhibitor Use in Patients With Stage III Colon Cancer. Journal of the National Cancer Institute, 2015, 107, 345.	6.3	115
100	Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance). PLoS ONE, 2014, 9, e99816.	2.5	65
101	Post Diagnosis Diet Quality and Colorectal Cancer Survival in Women. PLoS ONE, 2014, 9, e115377.	2.5	74
102	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. Oncologist, 2014, 19, 637-638.	3.7	292
103	Can we change the past for colorectal cancer patients and how do we move forward?. Cancer, 2014, 120, 1450-1452.	4.1	2
104	Response. Journal of the National Cancer Institute, 2014, 106, dju181-dju181.	6.3	0
105	Tumor LINE-1 Methylation Level and Microsatellite Instability in Relation to Colorectal Cancer Prognosis. Journal of the National Cancer Institute, 2014, 106, .	6.3	58
106	Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Molecular Cancer, 2014, 13, 135.	19.2	121
107	Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. Supportive Care in Cancer, 2013, 21, 2537-2545.	2.2	82
108	Impact of Physical Activity After Cancer Diagnosis on Survival in Patients With Recurrent Colon Cancer: Findings From CALGB 89803/Alliance. Clinical Colorectal Cancer, 2013, 12, 233-238.	2.3	31

#	ARTICLE	IF	CITATIONS
109	Association between physical activity and mortality in colorectal cancer: A meta-analysis of prospective cohort studies. <i>International Journal of Cancer</i> , 2013, 133, 1905-1913.	5.1	160
110	Comparison of Dietary and Lifestyle Habits Among Stage III and Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013, 12, 95-102.	2.3	17
111	Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2013, 31, 4465-4470.	1.6	313
112	Exercise after cancer diagnosis: time to get moving. <i>Oncology</i> , 2013, 27, 585-6, 588.	0.5	1
113	Perioperative chemotherapy for colorectal cancer liver metastases. <i>Oncology</i> , 2013, 27, 1088-90.	0.5	1
114	Dietary Glycemic Load and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1702-1711.	6.3	163
115	Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival. <i>New England Journal of Medicine</i> , 2012, 367, 1596-1606.	27.0	752
116	The Role of Obesity in Cancer Survival and Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1244-1259.	2.5	248
117	Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2012, 7, e38231.	2.5	48
118	Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 223-230.	3.8	0
119	Reported behavior of eating anything at anytime and risk of colorectal cancer in women. <i>International Journal of Cancer</i> , 2012, 130, 1395-1400.	5.1	4
120	Beyond Standard Adjuvant Therapy for Colon Cancer: Role of Nonstandard Interventions. <i>Seminars in Oncology</i> , 2011, 38, 533-541.	2.2	30
121	Impact of smoking on patients with stage III colon cancer. <i>Cancer</i> , 2010, 116, 957-966.	4.1	57
122	Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. <i>Journal of Pathology</i> , 2010, 222, 350-366.	4.5	424
123	Energetics in Colorectal and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4066-4073.	1.6	61
124	Adjuvant therapy for stage II and III colon cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 772-4.	0.3	2
125	Physical Activity and Male Colorectal Cancer Survival. <i>Archives of Internal Medicine</i> , 2009, 169, 2102.	3.8	223
126	Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype. <i>Clinical Cancer Research</i> , 2009, 15, 6412-6420.	7.0	350

#	ARTICLE	IF	CITATIONS
127	Insulin, the Insulin-Like Growth Factor Axis, and Mortality in Patients With Nonmetastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 176-185.	1.6	208
128	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. <i>Gut</i> , 2009, 58, 90-96.	12.1	682
129	Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men. <i>Gastroenterology</i> , 2008, 134, 21-28.	1.3	224
130	Impact of Body Mass Index and Weight Change After Treatment on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From Cancer and Leukemia Group B 89803. <i>Journal of Clinical Oncology</i> , 2008, 26, 4109-4115.	1.6	245
131	Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741. <i>Clinical Cancer Research</i> , 2008, 14, 8263-8269.	7.0	52
132	Association of Dietary Patterns With Cancer Recurrence and Survival in Patients With Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 754.	7.4	369
133	Physical Activity and Survival After Colorectal Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 2006, 24, 3527-3534.	1.6	762
134	Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Based Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2006, 6, 59-65.	2.3	10
135	Impact of Physical Activity on Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803. <i>Journal of Clinical Oncology</i> , 2006, 24, 3535-3541.	1.6	664
136	Systemic Therapy for Colorectal Cancer. <i>New England Journal of Medicine</i> , 2005, 352, 476-487.	27.0	1,034
137	Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1402-1410.	2.5	18
138	Assessment of a Dietary Questionnaire in Cancer Patients Receiving Cytotoxic Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8453-8460.	1.6	23
139	Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 914.	7.4	411
140	Impact of Body Mass Index on Outcomes and Treatment-Related Toxicity in Patients With Stage II and III Rectal Cancer: Findings From Intergroup Trial 0114. <i>Journal of Clinical Oncology</i> , 2004, 22, 648-657.	1.6	247
141	Epidermal growth factor receptor inhibitors and colorectal cancer. <i>Oncology</i> , 2004, 18, 35-8.	0.5	3
142	Follow-up strategies after curative resection of colorectal cancer. <i>Seminars in Oncology</i> , 2003, 30, 349-360.	2.2	58
143	Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. <i>Cancer</i> , 2003, 98, 484-495.	4.1	285
144	Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 433-440.	1.6	368

#	ARTICLE	IF	CITATIONS
145	Association of Hospital Procedure Volume and Outcomes in Patients with Colon Cancer at High Risk for Recurrence. <i>Annals of Internal Medicine</i> , 2003, 139, 649.	3.9	107
146	Adjuvant therapy in gastric cancer: can we prevent recurrences?. <i>Oncology</i> , 2003, 17, 714-21, 728; discussion 728-9, 732-3.	0.5	8
147	Chemotherapy options for gastric cancer. <i>Seminars in Radiation Oncology</i> , 2002, 12, 176-186.	2.2	14